The generic Favipiravir in India will be launched in India under the brand name ‘Favivir’, Hetero Labs, part of Hetero group announced on Wednesday
Quoting from a press release issued by the city-based drug maker, The Financial Express reported that the Drug Controller General of India (DCGI) has granted Hetero the manufacturing and marketing approval for Favipiravir.
Favivir is the second drug developed by Hetero after Covifor (Remdesivir) used in the treatment of COVID-19, the report said.
About Favivir
- It is an oral antiviral medication that has demonstrated positive clinical outcomes
- It improves treatment accessibility to a significant amount of COVID-19 patient population, which usually sustains mild to moderate symptoms
- It is priced at Rs 59 per tablet and is marketed and distributed by Hetero Healthcare Ltd
- The product is available from July 29 at all retail medical outlets and hospital pharmacies across the country and will be sold only on prescription, the report added.
